Insight
Summary of regulatory developments Updates for July 2022
We highlight the latest noteworthy items in the life insurance industry from various regulatory agencies for July 2022.
An increase in healthcare costs has led governments, health regulators and other payers to assess various options available to them to control costs. A common strategy that is implemented to mitigate the impact of rising healthcare costs is a move from fee-for-service reimbursement mechanisms to various types of bundled reimbursements, such as diagnosis-related groups (DRGs) or capitation payments. This paper considers the role of reimbursement mechanisms, and particularly DRG price adjustors, in directing general policy and specifically in the role of value-based healthcare.
Insight
We highlight the latest noteworthy items in the life insurance industry from various regulatory agencies for July 2022.
We’re here to help you break through complex challenges and achieve next-level success.
The role of reimbursement mechanisms and payment adjustors in value-based healthcare
This paper considers the role of reimbursement mechanisms, and particularly diagnosis-related groups price adjustors, in directing general policy and specifically in the role of value-based healthcare.